Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00789581 · ClinicalTrials.gov registry record · Phase 3
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
A Phase 3 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 3
- Development phase
- 614
- Enrollment target
NCT00789581: Completed Phase 3 study, sponsored by SCRI Development Innovations.
NCT00789581 is a Phase 3 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 614 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00789581, a Phase 3 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 614 participants
- Enrollment target
Study Summary
This is a randomized, Phase III, open-label, multicenter study.
Primary Outcome
The percentage of participants with disease-free survival at 3 and 5 years. Disease-free survival (DFS) is measured from the time between randomization and the date of first documented disease recurrence, or death from any cause.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Ixabepilone (Ixempra)
- DRUG Paclitaxel (Taxol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 614 participants |
| Start Date | 2008-12 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
What the finished NCT00789581 record still lists
NCT00789581 is an interventional study that assigns participants to a tested intervention. The registered 614 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00789581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00789581 about?
NCT00789581 is a clinical study titled "A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer". This is a randomized, Phase III, open-label, multicenter study.
What is the current status of trial NCT00789581?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 614 participants. The study started on 2008-12. Estimated completion is 2016-11.
What interventions are being tested in trial NCT00789581?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Ixabepilone (Ixempra) (DRUG), Paclitaxel (Taxol) (DRUG).
Who is sponsoring clinical trial NCT00789581?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00789581's enrollment target sits among peer trials
614 593rd of 2000 higher than 1,403 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
- NCT05006716 · 614 participants · Phase 1
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- NCT06170788 · 614 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- NCT07409272 · 614 participants · Phase 3
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia